Updated: 15 hours ago
Medically Reviewed by Dr. Wang, Medical Editor, ChinaCureLink
Most online lists of China's best breast cancer hospitals rank private clinics by reviews and enquiry volume. China's own specialty ranking tells a different story. Peking Union Medical College Hospital in Beijing, West China Hospital in Chengdu and Ruijin Hospital in Shanghai lead the national breast cancer list on Youlai, a ranking built on the Fudan University hospital specialty rankings. All three are Grade 3A public teaching hospitals with dedicated breast surgery departments.
For an international patient, knowing the names is only the first step. The harder questions are which hospital fits a specific diagnosis, which specialist to see, and what China offers that may not be available at home.
Key Takeaways |
• Peking Union Medical College Hospital, West China Hospital and Ruijin Hospital rank first, second and third on Youlai's national breast cancer list. • Their breast departments rank #1, #3 and #5 nationally on the Fudan specialty ranking that the list is based on. • China approved two Chinese-developed breast cancer drugs in 2026: trastuzumab rezetecan for previously treated HER2-positive disease and dalpiciclib for high-risk early HR-positive disease. • Some cell therapies are available only in the Hainan Boao Lecheng pilot zone and are not nationally approved treatments. • A Chinese specialist can review a case by video before the patient decides whether to travel. |
How China's Top Breast Cancer Hospitals Are Ranked
China has no single official "best hospital" list. The most widely cited benchmark is the Fudan University Hospital Management Institute's specialty ranking, which scores each hospital department mainly on peer reputation among Chinese specialists. Youlai, a major Chinese health platform, combines that ranking with hospital grade, health authority information and local reputation to produce its disease-level lists.
Two details matter when reading these rankings. First, the ranks apply to the breast surgery department, not to the hospital as a whole. Second, all three leading hospitals are Grade 3A, the highest tier in China's hospital grading system, which signals size, staffing and teaching status rather than outcomes for any single cancer.
Table of Content
The Top 3 Breast Cancer Hospitals in China
Peking Union Medical College Hospital, Beijing
Peking Union Medical College Hospital (PUMCH) holds the #1 national rank for breast surgery on the Fudan specialty list. China's National Health Commission designates it a national guidance center for diagnosing and treating complex and critical cases. It was also one of the first Chinese hospitals to take on medical care for foreign visitors, and it is a national base for medical education and research.
West China Hospital, Sichuan University, Chengdu
West China Hospital's breast surgery department ranks #3 nationally. Founded in 1892, the hospital serves as the national center for complex and critical cases in western China and is one of the country's leading medical schools and research bases.
Ruijin Hospital, Shanghai
Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, ranks #5 nationally for its Breast Disease Diagnosis and Treatment Center. Founded in 1907 as Guangci Hospital, it is a large Grade 3A teaching hospital with 2,442 approved beds across several campuses.
Leading Breast Cancer Specialists at These Hospitals
Each hospital's breast team includes chief physicians who specialize in breast cancer.
Prof. Sun Qiang (PUMCH) has specialized in breast disease since 1988 and has performed more than 6,000 breast cancer operations. He developed a breast-conserving technique using a periareolar incision.
Prof. Mao Feng (PUMCH) combines breast cancer surgery with chemotherapy and endocrine therapy, and has trained under Prof. Sun Qiang since 2003.
Prof. Lü Qing (West China Hospital) focuses on early diagnosis, breast function preservation and reconstruction, and standardized breast cancer treatment.
Prof. Li Hongjiang (West China Hospital) treats breast cancer, breast sarcoma and benign breast tumors.
Prof. Shen Kunwei (Ruijin Hospital) treats invasive and in situ breast cancer as well as benign breast disease.
Dr. Li Yafen (Ruijin Hospital) is a member of the Breast Cancer Committee of the China Anti-Cancer Association and has taken part in several clinical trials in China.
China's Recent Advances in Breast Cancer Treatment
Chinese-Developed Targeted Drugs
Two breast cancer approvals in 2026 came from Chinese drug developer Hengrui. In March 2026, China's National Medical Products Administration (NMPA) approved trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate. It is approved for adults with locally advanced or metastatic HER2-positive breast cancer who have already received at least one anti-HER2 treatment.
In June 2026, the NMPA approved dalpiciclib, a Chinese-developed CDK4/6 inhibitor, as post-surgery treatment for high-risk early-stage HR-positive, HER2-negative breast cancer. The approval followed a phase III study of 5,274 patients.
Both drugs are approved in China, but approval elsewhere may differ. Patients should confirm with their own oncologist how either drug would fit into their treatment plan.
Hainan Cell Therapies Used Alongside Standard Care
The Boao Lecheng International Medical Tourism Pilot Zone in Hainan can approve certain cell therapies for clinical use before nationwide approval. Three of its approved technologies list breast cancer or apply to it:
Autologous NK cell therapy at West China Lecheng Hospital, used alongside surgery, chemotherapy, radiotherapy or targeted drugs for eight solid tumors including breast cancer.
Oncolytic virus M1 therapy at Shulan (Boao) Hospital, for liver cancer and triple-negative breast cancer.
Personalized dendritic cell (DC) vaccine at West China Lecheng Hospital, given after surgery or chemoradiotherapy to help prevent recurrence. More detail is in ChinaCureLink's guide to personalized cancer vaccines in China.
These therapies are available only inside the pilot zone and are not nationally approved treatments. They are used as add-ons to standard care, not replacements for it, and eligibility is decided case by case.
What International Patients Should Know Before Seeking Treatment in China
A top ranking does not mean a hospital is the right fit for every patient. Three practical challenges come up most often.
Matching the hospital to the diagnosis. Breast cancer care depends heavily on hormone receptor and HER2 status, stage and previous treatment. The right hospital and specialist for a patient with relapsed HER2-positive disease may differ from the best choice for newly diagnosed triple-negative cancer.
Getting an appointment. Leading public hospitals book specialists through official Chinese-language channels, and senior doctors are in high demand. Pathology reports, scans and treatment records usually need translation before a specialist can review them.
Telling approved care apart from pilot-zone options. Nationally approved drugs, hospital clinical trials and Hainan pilot-zone therapies have different evidence levels and access rules. Patients who travel without checking this first may arrive for a treatment they do not qualify for.
How ChinaCureLink Helps Patients Compare Hospitals Before Travel
ChinaCureLink, a Medebound HEALTH company, is an independent medical facilitator that represents the patient rather than any single hospital and takes no hospital commission. Its team reviews the diagnosis, pathology, biomarkers and treatment history, then compares up to three suitable Chinese hospitals and specialists.
Before any travel decision, ChinaCureLink can arrange a video second opinion with the chosen specialist. There is no fee to apply, and a moderate on-site service fee applies only if the patient travels. If the patient decides to proceed, ChinaCureLink coordinates the appointment, records translation, hospital communication, travel and in-China support. Patients considering other routes can read ChinaCureLink's guide to choosing an independent medical facilitator in China.
Breast Cancer Case Studies From China
Case 1: A Hong Kong Patient Keeps Her Breast After Pre-Surgery Chemotherapy in Shanghai
Mei, a 45-year-old woman from Hong Kong, found a breast lump in February 2024, and imaging and a needle biopsy confirmed breast cancer. Her grandmother had undergone a full mastectomy when young, and Mei wanted to avoid losing her breast. Her husband studied international guidelines and consulted cancer specialists in the United States, Canada, Hong Kong and mainland China before the couple chose an international hospital in Shanghai.
After an hour-long consultation, the hospital's lead oncologist recommended chemotherapy before surgery to shrink the tumor and improve the chance of breast conservation. Mei began treatment in March. After six cycles, an MRI showed the mass was no longer visible and the lymph nodes had clearly shrunk.
Breast-conserving surgery followed on 11 July. Pathology four days later found no remaining tumor cells, a pathologic complete response. She then completed 16 sessions of whole-breast radiotherapy using deep-inspiration breath-hold and hypofractionation, techniques that limit radiation to the heart and lungs, alongside targeted therapy.
Case 2: An 8 cm Triple-Negative Tumor Reduced Enough for Breast-Conserving Surgery
Ms. Zhou, a 52-year-old woman, waited three to four months after noticing a breast lump, until it grew rapidly within a month. A needle biopsy at a public hospital in Shenzhen confirmed triple-negative breast cancer, the most aggressive subtype, with an 8 cm tumor at locally advanced stage IIB. Her surgeon judged that breast conservation was not possible at that point.
The team gave six cycles of TAC chemotherapy before surgery, checking the response by examination and imaging every two cycles. The tumor shrank from 8 cm to about 3 cm. Surgeons then performed breast-conserving surgery with clear margins. All three sentinel lymph nodes were negative, so she avoided full removal of the underarm lymph nodes.
International patients facing a large or aggressive tumor can ask the same question: whether treatment before surgery could make breast conservation possible. ChinaCureLink can arrange a review of the case with a Chinese breast specialist before any travel decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Can international patients be treated at Peking Union Medical College Hospital?
Yes. PUMCH was one of the first Chinese hospitals to provide medical care for foreign visitors. Appointments with senior breast surgeons are booked through the hospital's official channels, and medical records usually need translation into Chinese first.
How much does breast cancer treatment in China cost?
Cost depends on the stage, the treatment plan, the hospital and the length of stay, so a reliable figure is only possible after a specialist reviews the case. Pilot-zone therapies in Hainan are priced separately from standard hospital care. Patients should ask for a written estimate that lists what is and is not included.
Is HER2-positive breast cancer treatment available in China?
Yes. Standard HER2-targeted therapies are widely used at major Chinese hospitals. In March 2026, China also approved trastuzumab rezetecan, a Chinese-developed HER2-targeted drug, for adults with advanced HER2-positive breast cancer who have already received anti-HER2 treatment.
Can a Chinese breast cancer specialist review a case before travel?
Yes. With translated records, a specialist can give an opinion by video before the patient commits to travel. This helps confirm whether a hospital or therapy is suitable and avoids unnecessary trips.
Conclusion
Peking Union Medical College Hospital, West China Hospital and Ruijin Hospital lead China's national breast cancer ranking, each with an experienced breast surgery team. China has also added new options in 2026, including two Chinese-developed targeted drugs and several pilot-zone cell therapies in Hainan. The best choice still depends on the individual diagnosis, so a specialist review before travel is the safest first step.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
References
Youlai. National breast cancer hospital ranking (全国治疗乳腺癌医院排行榜), accessed 30 Oct 2026. https://m.youlai.cn/hospitalrank/0_x_273.html
Youlai doctor profiles: Sun Qiang, Mao Feng (PUMCH); Lü Qing, Li Hongjiang (West China Hospital); Shen Kunwei, Li Yafen (Ruijin Hospital). https://m.youlai.cn/yyk/docindex/19292/
Jiangsu Hengrui Medicine. Announcement on approval of a new indication for trastuzumab rezetecan, 20 March 2026. https://static.cninfo.com.cn/finalpage/2026-03-21/1225020909.PDF
Dalpiciclib adjuvant approval, 16 June 2026. https://filingreader.com/news-wire/shanghai/2026-06-16/hengrui-medicine-wins-breast-cancer-approval-and-prostate-drug-trial
Boao Lecheng approved cell therapy projects, March 2026. https://m.sohu.com/a/1001185537_122497153
Boao Lecheng 58 approved biomedical technologies, July 2026. http://m.elecheng.cn/h-nd-630.html
Shangguan News. Hong Kong patient completes neoadjuvant treatment and breast-conserving surgery in Shanghai, 1 November 2024. https://www.163.com/dy/article/JFU5F4EO055040N3.html
Shenzhen Third People's Hospital. Neoadjuvant treatment enables breast conservation for an 8 cm tumor, 16 April 2026. https://www.szsdsrmyy.com/xxgk/xwzx/xwdt/content/post_1671159.html
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
